NCT00599326View on ClinicalTrials.gov

Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda

PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Porphyria Cutanea Tarda
Interventions
DRUG

Deferasirox

250 mg of deferasirox once daily for 6 months

Trial Locations (1)

75390-8802

UT Southwestern Medical Center at Dallas - Dermatology Clinical Trials, Dallas

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER